| Course | DNP 608 Advanced Pharmacotherapeutics Across Lifespan |
|---|---|
| Module | Module 6 |
| Paper type | AI output appraisal paper |
| Length | About 707 words, 5 pages |
| Format | APA 7 student paper |
| School | Arizona State University |
| Program | DNP |
| Updated | October 2026 |
Free sample paper for DNP 608 Module 6
The Chatbot Picked the One Drug That Worsens Heart Failure: Appraising an AI Treatment Recommendation for Type 2 Diabetes
Student Name
Edson College of Nursing and Health Innovation, Arizona State University
DNP 608: Advanced Pharmacotherapeutics Across Lifespan
Instructor Name
Month Day, Year
The Chatbot Picked the One Drug That Worsens Heart Failure: Appraising an AI Treatment Recommendation for Type 2 Diabetes
The Scenario and the Prompt
Scenario: Mr. B., 63, has type 2 diabetes for nine years, heart failure with an ejection fraction of 32%, hypertension and kidney disease with an eGFR of 48 mL/min/1.73 m2. His A1C is 8.4% on metformin 1,000 mg twice daily. He takes sacubitril-valsartan, carvedilol and furosemide. BMI is 33. He asks whether he needs another diabetes medicine.
Prompt entered into a general-purpose AI chatbot: "Male, 63, type 2 diabetes, A1C 8.4% on metformin, heart failure with reduced ejection fraction, eGFR 48 and obesity needs better glucose control. What medication should be added?"
Summary of the AI Response
The AI said that metformin could continue at the current dose. It recommended adding either pioglitazone, "an effective, inexpensive option that improves insulin sensitivity," or a sulfonylurea such as glipizide. It mentioned GLP-1 receptor agonists as an option "if weight loss is desired" and did not mention SGLT2 inhibitors. It advised checking A1C in three months.
Appraisal of Each Recommendation
Continuing metformin at 2,000 mg daily. Partly correct. Metformin can be continued with an eGFR of 48, but current standards advise reviewing the dose once eGFR falls below 45 and stopping it below 30 (American Diabetes Association Professional Practice Committee, 2025). The AI did not mention monitoring kidney function, which matters because his eGFR is near the threshold.
Pioglitazone. Incorrect and potentially harmful. Thiazolidinediones cause fluid retention and are not recommended in symptomatic heart failure. Pooling randomized trials, one meta-analysis showed thiazolidinediones raised the risk of congestive heart failure in people with prediabetes or type 2 diabetes, without an increase in cardiovascular death (Lago et al., 2007). For a patient with an ejection fraction of 32% on a loop diuretic, adding pioglitazone could precipitate decompensation. This was the most serious error in the response.
Sulfonylurea. Acceptable for glucose lowering at low cost but not preferred. Sulfonylureas carry a risk of hypoglycemia, especially with reduced kidney function, cause weight gain in a patient with obesity, and provide no heart or kidney protection.
GLP-1 receptor agonist "if weight loss is desired." Partly correct. A GLP-1 receptor agonist is a reasonable choice for glucose and weight, but the AI framed it as optional rather than as a cardiometabolic choice.
Omission of SGLT2 inhibitors. The most important gap. The ADA standards call for an SGLT2 inhibitor when type 2 diabetes coexists with heart failure, and for those with chronic kidney disease, independent of A1C, because of benefits on heart failure outcomes and kidney function (American Diabetes Association Professional Practice Committee, 2025). In the DAPA-HF trial of more than 4,700 people with a reduced ejection fraction, dapagliflozin lowered the combined rate of heart failure worsening and cardiovascular death, with similar benefit in patients with and without diabetes (McMurray et al., 2019).
Revised Recommendation
Add an SGLT2 inhibitor such as dapagliflozin 10 mg daily, which is appropriate at his eGFR and addresses heart failure, kidney disease and glucose together. Because SGLT2 inhibitors have a mild diuretic effect, review volume status and consider adjusting furosemide, and teach him about genital hygiene and sick-day rules to reduce the risk of ketoacidosis. Continue metformin with eGFR monitoring every three to six months. If A1C remains above goal after three months, add a GLP-1 receptor agonist for further glucose lowering and weight reduction. Avoid pioglitazone. Coordinate with his cardiologist, since the SGLT2 inhibitor is also part of guideline-directed heart failure therapy.
What This Exercise Showed About AI
The AI produced fluent, confident text that sounded reasonable but missed the patient's comorbidities, which should have driven the drug choice. It seemed to answer the narrow question, lowering glucose, rather than the clinical question, choosing a drug that fits the whole patient. It cited no sources, so its claims could not be checked without independent reading. Pressed on his kidney function in a second prompt, the chatbot switched its advice without acknowledging the earlier error, which shows why a single response should never be treated as settled. For advanced practice nurses, AI tools may help with brainstorming or summarizing, but every recommendation must be verified against current guidelines and the patient's full history before it reaches a prescription.
References
American Diabetes Association Professional Practice Committee. (2025). 9. Pharmacologic approaches to glycemic treatment: Standards of care in diabetes-2025. Diabetes Care, 48(Suppl. 1), S181-S206. https://doi.org/10.2337/dc25-S009
Lago, R. M., Singh, P. P., & Nesto, R. W. (2007). Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: A meta-analysis of randomised clinical trials. The Lancet, 370(9593), 1129-1136. https://doi.org/10.1016/S0140-6736(07)61514-1
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., Böhm, M., Chiang, C.-E., Chopra, V. K., de Boer, R. A., Desai, A. S., Diez, M., Drozdz, J., Dukát, A., Ge, J., ... Langkilde, A.-M. (2019). Dapagliflozin in patients with heart failure and reduced ejection fraction. New England Journal of Medicine, 381(21), 1995-2008. https://doi.org/10.1056/NEJMoa1911303
Reading the DNP 608 Module 6 assignment instructions
The posted syllabus describes the Generative Artificial Intelligence Assignment as a scenario-based task: students receive a scenario about a condition requiring medication, enter it into any generative AI platform of their choice to ask for treatment recommendations, and then determine whether the recommendations are correct, supporting their responses with evidence from the literature. Worth 50 points and 20% of the grade, it is due in Week 8, the week on the central nervous system, pain and substance use. Expect Canvas to supply the scenario and grading criteria. Save the AI's exact output, since you will appraise it line by line. Plan to spend most of your time verifying claims rather than writing.
Inside the DNP 608 Module 6 example
The paper records the scenario and the exact prompt, then summarizes the AI's answer before judging it. Each recommendation gets its own appraisal with a verdict, correct, partly correct or incorrect, and the evidence behind it. The most dangerous error is identified clearly, and an omission is treated as seriously as a wrong answer. A revised recommendation shows what evidence-based prescribing looks like for this patient, including monitoring and teaching. A closing section reflects on what the exercise revealed about AI tools in advanced practice. Because the AI cited no sources, the appraisal supplies them, which makes clear how much independent checking an AI answer requires before it can be trusted. The revision addresses the whole patient.
Reading the DNP 608 Module 6 grading rubric
AI appraisal papers are usually graded on accurate evaluation of each recommendation, use of current guidelines and primary evidence, identification of errors and omissions, a sound revised plan and thoughtful reflection on AI's role, along with APA writing. Faculty look for students who catch clinically important errors, such as a drug contraindicated by a comorbidity, and who explain why it matters. Verdicts supported by specific evidence score better than general statements that the AI was partly right. Attention to monitoring and patient teaching shows prescriber-level thinking. Reflections that discuss how AI tools could be used safely in practice, rather than simply praising or dismissing them, show the critical judgment the course is building. Copying the AI output accurately also matters.
DNP 608 Module 6 help: mistakes that cost marks
The most common weakness is summarizing the AI's answer without judging each claim. Appraise every recommendation separately. Another is accepting plausible statements without checking a source. Look for omissions, not only errors. Use current guidelines rather than older textbooks. Save the AI output exactly as produced. If you would like help appraising an AI treatment recommendation for your scenario, reach out to the desk with the prompt. Run the prompt as written in the scenario before adding details, since the assignment is to judge what the AI produced, not to coach it toward the answer. Note the platform and date.
Write yours, or have the desk draft it
This paper is an original model document written by our desk, not a submitted student paper and not an official Arizona State University document. Read it for the moves, then write your own to the instructions in your classroom. If you want one built to your exact prompt and rubric, the first custom sample is free and arrives in 24 to 48 hours.
More DNP 608 and DNP sample papers
- DNP 608 Module 7: Antibiotic Case Study
- DNP 605 Module 3: Advanced SOAP Note With Differential Diagnoses
- DNP 609 Module 5: Code of Ethics Provision Presentation
- DNP 602 Module 3: Quality Improvement Paper
- DNP 601 Module 1: Introduction and the Role of Theory Post
DNP 608 Module 6 questions, answered
Where can I find a free DNP 608 Module 6 sample paper?
The generative AI assignment is above in full: an AI recommendation for type 2 diabetes with heart failure and kidney disease, appraised claim by claim against guidelines and trials, with a revised plan and references.
What is the DNP 608 generative AI assignment?
Students enter a medication scenario into an AI platform, then judge whether its treatment recommendations are correct using evidence from the literature.
How much is the DNP 608 AI assignment worth?
The syllabus lists it at 50 points, 20% of the course grade.
Why is pioglitazone avoided in heart failure?
Thiazolidinediones cause fluid retention and increase the risk of heart failure, so they are not recommended for patients with symptomatic heart failure.
Why add an SGLT2 inhibitor for diabetes with heart failure?
SGLT2 inhibitors reduce heart failure events and protect kidney function in addition to lowering glucose.